Research & Development
RhoVac completes patient recruitment for prostate cancer trial
20 September 2021 -

Swedish cancer immunotherapy company RhoVac AB (Spotlight:RHOVAC) announced on Monday that patient recruitment has been completed for its clinical phase IIb study of lead drug candidate RV001 in prostate cancer.

RhoVac started the BRaVac trial in late 2019, targeting prostate cancer patients with a biochemical recurrence (a rise in PSA) after curative intent therapy. In November 2020 RhoVac was awarded Fast Track Designation by the US Food and Drug Administration (FDA) for RV001 in this cancer indication.

The objective of the study is to show that RV001 can significantly prevent or delay disease progression in these patients, something for which no standard therapy is currently available.

Top-line results are estimated to be available in the first half of 2022.



Related Headlines